Država: Irska
Jezik: engleski
Izvor: HPRA (Health Products Regulatory Authority)
DONEPEZIL HYDROCHLORIDE
McDermott Laboratories Ltd t/a Gerard Laboratories
N06DA02
DONEPEZIL HYDROCHLORIDE
5 Milligram
Orodispersible Tablet
Product subject to prescription which may not be renewed (A)
Anticholinesterases
Authorised
2010-07-16
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT ARIPIL OROTAB 5 MG ORODISPERSIBLE TABLETS ARIPIL OROTAB 10 MG ORODISPERSIBLE TABLETS (donepezil hydrochloride) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Aripil Orotab is and what it is used for 2. What you need to know before you take Aripil Orotab 3. How to take Aripil Orotab 4. Possible side effects 5. How to store Aripil Orotab 6. Contents of the pack and other information 1. WHAT ARIPIL OROTAB IS AND WHAT IT IS USED FOR Aripil Orotab contains the active substance donepezil hydrochloride. Donepezil hydrochloride belongs to a group of medicines called acetylcholinesterase inhibitors. Donepezil hydrochloride increases the levels of a substance (acetylcholine) in the brain involved in memory function by slowing down the breakdown of that substance. It is used to treat the symptoms dementia in people diagnosed as having of mild to moderately severe Alzheimer’s disease. Symptoms of the illness include increasing memory loss, confusion and behavioural changes. As a result, sufferers of Alzheimer’s disease find it more difficult to carry out their normal daily activities. It is for use in adult patients only. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE ARIPIL OROTAB Pročitajte cijeli dokument
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Aripil Orotab 5 mg Orodispersible tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 5 mg tablet contains 5 mg donepezil hydrochloride (as monohydrate), equivalent to 4.56 mg of donepezil free base. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Orodispersible tablet Aripil Orotab 5 mg are white coloured round flat bevelled edged tablets, debossed with “DL 5” on one side and “M” on the other side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Aripil Orotab is indicated for the symptomatic treatment of mild to moderately severe Alzheimer's dementia. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _ADULTS/ELDERLY_ Treatment is initiated at 5 mg/day (once-a-day dosing). The 5 mg/day dose should be maintained for at least one month in order to allow the earliest clinical responses to treatment to be assessed and to allow steady-state concentrations of donepezil hydrochloride to be achieved. Following a one-month clinical assessment of treatment at 5 mg/day, the dose of donepezil hydrochloride can be increased to 10 mg/day (once-a-day dosing). The maximum recommended daily dose is 10 mg. Doses greater than 10 mg/day have not been studied in clinical trials. Treatment should be initiated and supervised by a physician experienced in the diagnosis and treatment of Alzheimer's dementia. Diagnosis should be made according to accepted guidelines (e.g. DSM IV, ICD 10). Therapy with donepezil hydrochloride should only be started if a caregiver is available who will regularly monitor drug intake for the patient. Maintenance treatment can be continued for as long as a therapeutic benefit for the patient exists. Therefore, the clinical benefit of donepezil hydrochloride should b Pročitajte cijeli dokument